Stock search

Ticker or company name

Gilead Sciences

GILD · NASDAQ · Biotechnology

$167,58Down −0,50 (−0,30%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$208 bn
Div. yield
4,0%
Year to date
+36,9%
52 weeks: $116,88$176,58

Ratio score

25/100
Ratio would not consider buying

based on 8 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

1 ✓ · 2 — · 5 ✕ · 2 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTMn/a18,642,1
Forward P/E20,9—18,7
PEGn/a—4,1
P/S6,73,86,6
EV/EBITDA18,815,328,2
P/FCF15,1—26,0
P/B16,15,19,8

Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 36 analysts

Buy
30
Hold
6
Sell
0

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20262,232,55Up +14,3%
Q2 2026−7,38−6,75Up +8,5%
Q1 20261,952,03Up +4,0%
Q4 20251,851,86Up +0,7%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue8,30 bn7,80 bn6,96 bn7,93 bn7,77 bn7,08 bn6,67 bn7,57 bn7,55 bn6,95 bn6,69 bn7,11 bn
EPS1,94−8,451,611,742,431,561,041,421,001,29−3,341,13
Margin29,3%−134,5%29,0%27,5%39,3%27,7%19,7%23,6%16,6%23,2%−62,4%20,1%
FCF4,80 bn3,43 bn2,43 bn3,12 bn3,96 bn720 m1,65 bn2,83 bn4,17 bn1,20 bn2,11 bn1,95 bn

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $106 m.

NameAmountSharesPrice
cain wettan keeley m6 Nov 2026 · sale$557 8103 399$164,11
o'day daniel patrick5 Nov 2026 · sale$1,72 m9 810$175,17
o'day daniel patrick4 Nov 2026 · sale$18,0 m102 619$175,16
o'day daniel patrick2 Nov 2026 · sale$342 1252 000$171,06
o'day daniel patrick2 Nov 2026 · sale$1,33 m7 796$170,35
o'day daniel patrick2 Nov 2026 · sale$322 2961 904$169,27
o'day daniel patrick2 Nov 2026 · sale$285 7711 700$168,10
o'day daniel patrick2 Nov 2026 · sale$267 8401 600$167,40
o'day daniel patrick30 Oct 2026 · sale$2,78 m15 881$175,25
mercier johanna15 Oct 2026 · sale$468 6603 000$156,22
dickinson andrew d15 Oct 2026 · sale$468 6603 000$156,22
o'day daniel patrick1 Oct 2026 · sale$445 8803 000$148,63
o'day daniel patrick1 Oct 2026 · sale$1,77 m12 000$147,72
mercier johanna15 Sep 2026 · sale$87 174600$145,29
mercier johanna15 Sep 2026 · sale$115 566800$144,46

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Biotechnology
Exchange
NASDAQ
Country
US
IPO date
22 Jan 1992

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
AMGNAmgen$462,3267would watch26,8+8,2%24,1%
VRTXVertex Pharmaceuticals$537,7972would consider33,7+10,5%30,7%
REGNRegeneron Pharmaceuticals$952,4067would watch20,5+18,6%28,5%
MRNAModerna$215,2722would not consider—+13,1%−110,5%
ABBVAbbVie$294,5572would consider50,4+10,7%15,7%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.